Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

patient advocates

Shire Basingstoke

Shire links with US hospital for rare disease research

Willwork with Cincinnati Children's Hospital Medical Centre novel therapies

- PMLiVE

FDA grants orphan drug status to Treeway’s ALS treatment

Amyotrophic Lateral Sclerosis drug TW001 gainsregulatory benefits

- PMLiVE

UCB: Patient centricity should move a business forward

Pharma may become obsolete if it does not include the patient voice, says Lode Dewulf

Time to get personal about adherence

Patients must be offered support strategies based on their individual adherence barriers

Reconciling patient empowerment and EU regulations

To achieve true patient-centricity, regulatoryframeworks must be aligned with the real-world

- PMLiVE

The problem with pills

Conventional solid dosage forms have failed to keep pace with modern consumers’ evolving demands

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

- PMLiVE

Bupa launches UK ad campaign

TV campaign highlights support services for patients

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

- PMLiVE

RCGP animation to improve patient care

Encourages doctors to consider a holistic approach to care planning

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links